Actively Recruiting
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-04-01
250
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.
CONDITIONS
Official Title
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a potentially resectable lung nodule 8-40 mm in diameter suspected of clinical stage IA-IB lung cancer (node-negative, less than 4 cm)
- Plan to undergo surgery at Moffitt Cancer Center if surgery is recommended
- If stereotactic body radiotherapy (SBRT) is recommended instead of surgery, SBRT will be delivered at Moffitt Cancer Center
- Age over 18 years, male or female
- Have an ECOG performance status of 0-1
- Agree to participate in follow-up protocol
- Any suspected primary lung cancer cell type except typical carcinoid tumor, carcinoma in situ, or minimally-invasive carcinoma
- Ability to understand and willingness to sign written informed consent
You will not qualify if you...
- Currently receiving any cancer treatment
- Have uncontrolled intercurrent illness
- Had lung cancer within the last 5 years
- Have another active major cancer except non-melanoma skin cancer
- Have pure ground glass opacities (nodules) or hilar masses
- Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma)
- Suspected metastatic nodule in the lung from another cancer outside the lung
- Unable to provide informed consent
- Prisoner or incarcerated individual
- For surgical patients, have R1 or R2 resection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
Research Team
B
Brianna Aponte
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here